Abstract
The MLL gene, located at 11q23 band, is frequently disrupted by different chromosomal rearrangements that occur in a variety of hematological malignancies. MLL rearrangements are associated with distinct clinical features and a poor prognosis. The aim of this study was to analyze the incidence and the prognostic significance of MLL rearrangements in a consecutive series of adult AML patients and to determine the immunophenotypic features of these cases. The identification of abnormal immunophenotypes could be used for the detection of minimal residual disease (MRD). Ninety-three adult patients with de novo acute myeloid leukemia (AML) were analyzed by Southern blot in order to detect MLL rearrangements (MLL+). RT-PCR and genomic long-range PCR were performed to further characterize MLL partial tandem duplication (PTD) in those patients in whom conventional karyotype did not show 11q23 chromosomal translocations. All the patients were homogeneously immunophenotyped at diagnosis. MLL rearrangements were detected in 13 (14%) patients. Four patients (5%) showed 11q23 translocations by karyotypic conventional analysis. Nine patients (10%) revealed PTD of MLL and one patient showed a MLL cleavage pattern. The MLL+ patients usually expressed myeloid and monocytic antigens CD33 (12/13 cases), CD13 (9/13), CD117 (9/13), CD64 (11/13) and in some cases CD14 (4/11). HLA-DR was also positive in (12/13). Eight out of 13 cases expressed the stem cell marker CD34. Only one patient revealed lymphoid marker reactivity (CD7) and CD56 was expressed in 5/13 cases. All the MLL+ patients showed at least one aberrant phenotype at diagnosis, which allowed us to set out a simple panel for the MRD studies. Twenty-seven samples from eight patients in morphologic complete remission (CR) were analyzed using the aberrant immunologic combinations detected at diagnosis. Phenotypically abnormal cells were detected in all the patients who subsequently relapsed, whereas only one patient with MRD+ remained in CR. Owing to the high level of residual leukemic cells, the MLL+ patients showed a short CR duration and a poor survival. In conclusion, immunophenotyping may be a suitable approach to investigating MRD status in AML patients with PTD of the MLL gene.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Mrózek, K, Heinonen, K, de la Chapel, A & Bloomfield, C. Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol, (1997). 24, 17–31.
Rabbitts, TH Chromosomal translocations in human cancer. Nature, (1994). 372, 143–149.
Ziemin-van der Poel, S, McCabe, NR, Gill, HJ, Espinosa, R III, Patel, Y, Harden, A, Rubinelli, P, Smith, SD, LeBeau, MM, Rowley, JD & Diaz, MO Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. Proc Natl Acad Sci USA, (1991). 88, 10735–10739.
Rowley, JD Rearrangements involving chromosome band 11q23 in acute leukemia. Semin Cancer, (1993). 4, 377–385.
Lo Coco, F, Mandelli, F, Breccia, M, Annino, L, Guglielmi, C, Petti, MC, Testi, AM, Alimena, G, Croce, CM, Canaani, E & Cimino, G Southern blot analysis of ALL–1 rearrangements at chromosome 11q23 in acute leukemia. Cancer Res, (1993). 53, 3800–3803.
Cimino, G, Rapanotti, MC, Elia, L, Biondi, A, Fizzotti, M, Testi, AM, Tosti, S, Croce, CM, Canaani, E, Mandelli, F & Lo Coco, F ALL-1 gene rearrangements in acute myeloid leukemia: association with M4-M5 French–American–British classification subtypes and young age. Cancer Res, (1995). 55, 1625–1628.
Sorensen, P, Chen, C, Smith, F, Arthur, D, Domer, P, Bernstein, I, Korsmeyer, S, Hammond, G & Kersey, J Molecular rearrangements of the MLL gene are present in most cases of infant acute myeloid leukemia and are strongly correlated with monocytic or myelomonocytic phenotypes. J Clin Invest, (1994). 93, 429–437.
Caligiuri, MA, Strout, MP, Lawrence, D, Arthur, DC, Baer, MR, Yu, F, Knuutila, S, Mrózek, K, Oberkircher, AR, Marcucci, G, de la Chapelle, A, Elonen, E, Block, AM, Rao, PN, Herzig, GP, Powell, BL, Ruutu, T, Schiffer, CA & Bloomfield, C Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res, (1998). 58, 55–59.
Schnittger, S, Kinkelin, U, Schoch, C, Heinecke, A, Haase, D, Haferlach, T, Büchener, T, Wörmann, B, Hiddermann, W & Griesinger, F Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavourable subset of AML. Leukemia, (2000). 14, 796–804.
Di Martino, J & Cleary, ML MLL rearrangements in haematological malignancies: lessons from clinical and biological studies. Br J Haematol, (1999). 106, 614–626.
Rubnitz, JE, Behm, FG & Downing, JR 11q23 rearrangements in acute leukemia. Leukemia, (1996). 10, 4–82.
Mrózek, K, Heinonen, K, Lawrence, D, Carroll, AJ, Koduru, P, Rao, K, Strout, M, Hutchinson, R, Moore, J, Mayer, R, Schiffer, C & Bloomfield, C Adult patients with de novo acute myeloid leukemia and t(9;11)(p22;q23) have superior outcome to patients with other translocations involving band 11q23: a cancer and leukemia Group B study. Blood, (1997). 11, 4532–4538.
Orfao, A, Chillón, MC, Bortoluci, AM, López-Berges, MC, García-Sanz, R, Gonzalez, M, Tabernero, MD, García-Marcos, MA, Rasillo, AI, Hernández-Rivas, J & San Miguel, JF The flow cytometric pattern of CD34, CD15 and CD13 expression in acute myeloblastic leukemia is highly characteristic of the presence of PML/RARα gene rearrangements. Haematologica, (1999). 84, 405–412.
Borowitz, MJ, Rubnitz, J, Nash, M, Pullen, DJ & Cemitta, B Surface antigen phenotype can predict TEL-AML1 rearrangement in childhood B-precursor ALL: a Pediatric Oncology Group study. Leukemia, (1998). 12, 1764–1770.
Tabernero, MD, Bortoluci, AM, Alaejos, I, López-Berges, MC, Rasillo, A, García-Sanz, R, Sayagués, JM, González, M, San Miguel, JF & Orfao, A Adult precursor B-ALL with BCR/ABL gene rearrangements displays a unique pattern of CD10, CD34, CD13 and CD38 expression that can be used to screen for this translocation. Leukemia, (2001). 15, 406–414.
Tien, HF, Hsiao, CH, Tang, JL, Tsay, W, Hu, CH, Kuo, YY, Wang, CH, Chen, YC, Shen, MC, Lin, DT, Lin, KH & Lin, KS Characterization of acute myeloid leukemia with MLL rearrangements – no increase in the incidence of coexpression of lymphoid-associated antigens on leukemic blasts. Leukemia, (2000). 14, 1025–1030.
Baer, MR, Stewart, CC, Lawrence, D, Arthur, DC, Mrózek, K, Strout, MP, Davey, FR, Schiffer, CA & Bloomfield, CD Acute myeloid leukemia with 11q23 translocations: myelomonocytic immunophenotype by multiparameter flow cytometry. Leukemia, (1998). 12, 317–325.
Swansbury, GJ, Slater, R, Bain, BJ, Moorman, AV & Secker-Walker, LM on behalf of the European 11q23 Workshop participants Hematological malignancies with t(9;11)(p21-22;q23) – a laboratory and clinical study of 125 cases. Leukemia, (1998). 12, 792–800.
Satake, N, Sakashita, A, Kobayashi, H, Maseki, N, Sakurai, M & Kaneko, Y Minimal residual disease in acute monocytic leukemia patient with trisomy 11 and partial tandem duplication of MLL. Cancer Genet Cytogenet, (1997). 96, 26–29.
San Miguel, JF, Martínez, A, Macedo, A, Vidriales, MB, López-Berges, C, González, M, Caballero, D, García-Marcos, MA, Ramos, F, Fernández-Calvo, J, Calmuntia, MJ, Diaz-Mediavilla, & Orfao, A Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood, (1997). 90, 2465–2470.
Martinez, A, San Miguel, JF, Vidriales, MB, Ciudad, J, Caballero, MD, López-Berges, MC, Moro, MJ, Calmuntia, MJ, Ortega, F & Orfao, A An abnormal CD34+ myeloid/CD34+ lymphoid ratio at the end of chemotherapy predicts relapse in patients with acute myeloid leukemia. Cytometry, (1999). 38, 70–75.
Bennet, JM, Catovsky, D, Daniel, MT, Flandrin, G, Galton, DAG, Gralnick, H & Sultan, C Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French–American–British cooperative group. Ann Intern Med, (1985). 103, 620–626.
Cheson, BD, Cassileth, PA, Head, DR, Schiffer, CA, Bennet, JM, Bloomfield, CD, Brunning, R, Gale, RP, Grever, MR, Keating, MJ, Sawitsky, A, Stass, S, Weinstein, H & Woods, WG Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol, (1990). 8, 813–819.
Mitelman, F ISCN. An International System for Human Cytogenetic Nomenclature. S Karger:, (1995). Basel, 1995
Bene, MC, Castoldi, G, Knapp, W, Ludwing, WD, Matutes, E, Orfao, A & van't Veer, MB European Group for the Immunological Classification of Acute Leukemias Proposals for the immunological classification of acute leukemias. Leukemia, (1995). 9, 1783–1786.
Muñoz, L, López, O, Martino, R, Brunet, S, Bellido, M, Sierra, J & Nomdedéu, J Minimal residual disease detection with immunophenotype and RT-PCR in Philadelphia positive acute lymphoblastic leukemia. Hematologica, (2000). 85, 40–46.
Bernard, OA & Berger, R Molecular basis of 11q23 rearrangements in hematopoietic malignant proliferations. Genes Chromos Cancer, (1995). 13, 75–85.
Cimino, G, Rapanotti, MC, Sprovieri, T & Elia, L ALL1 gene alterations in acute leukemia: biological and clinical aspects. Haematologica, (1998). 83, 350–357.
Mitterbauer, G, Zimmer, C, Fonatsch, C, Haas, OA, Thalhammer-Scherrer, R, Schwarzinger, I, Kalhs, P, Jaeger, U, Lechner, K & Maannhalter, C Monitoring of minimal residual leukaemia in patients with MLL-AF9 positive acute myeloid leukaemia by RT-PCR. Leukemia, (1999). 13, 1519–1524.
Cimino, G, Elia, L, Rapanotti, MC, Sprovieri, T, Mancini, M, Cuneo, A, Mecucci, C, Fioritoni, G, Carotenuto, M, Morra, E, Liso, V, Annino, L, Saglio, G, De Rossi, G, Foá, R & Mandelli, F A prospective study of residual-disease monitoring of the ALL1/AF4 transcript in patients with t(4;11) acute lymphoblastic leukemia. Blood, (2000). 95, 96–101.
Schnittger, S, Wörmann, B, Hiddermann, W & Griesinger, F Partial tandem duplications of the MLL gene are detectable in peripheral blood and bone marrow of nearly all healthy donors. Blood, (1998). 92, 1728–1734.
Macintyre, E, Bourquelot, P & Leboeuf, D MLL cleavage occurs in approximately 5% of de novo acute myeloid leukemia, including in patients analyzed before treatment induction. Blood, (1997). 89, 2224–2226.
Poirel, H, Rack, K, Delabesse, E, Radford-Weiss, I, Troussard, X, Debert, C, Leboeuf, D, Bastard, C, Picard, F, Veil-Buzyn, A, Flandrin, G, Bernard, O & Macintyre, E Incidence and characterization of MLL gene (11q23) rearrangements in acute myeloid leukemia M1 and M5. Blood, (1996). 87, 2496–2505.
Acknowledgements
FIS 00/0352; L Muñoz is recipient of a Grant FIJC-99/ESP-GLAXO from the José Carreras International Leukemia Fundation. We thank the following centers and physicians for their participation in the CETLAM LMA-99 protocol: Institut Calalá d'Oncologia, Hospitalet (JJ Berlanga); Hospital de la Santa Creu i San Pau, Barcelona (L Muñoz, JF Nomdedéu, A Aventín, S Brunet, J Sierra); Hospital Josep Trueta, Girona (R Guardia, C Fernández); Hospital Joan XXIII, Tarragona (A Llorente); Hospital Verge de la Cinta, Tortosa (L Font); Hospital Clínic, Barcelona (N Villamor, D Colomer, J Esteve); Hospital Vall d'Hebrón, Barcelona (G Acebedo, J Bueno); Hospital Son Dureta, Mallorca (J Bargay); Hospital del Mar, Barcelona (C Pedro); Hospital Clínico, Valencia (M Tormo); Hospital Juan Canalejo, A Coruña (JP Torres); Hospital German Trias i Pujol, Badalona (JM Ribera); Hospital Arnau de Vilanova, Lleida (JM Sánchez); Hospital Clínico, Málaga (MP Queipo de Llano); Mútua de Terrassa, Terrassa (JM Martí); Clínica Teknon, Barcelona (P Vivancos).
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Muñoz, L., Nomdedéu, J., Villamor, N. et al. Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells. Leukemia 17, 76–82 (2003). https://doi.org/10.1038/sj.leu.2402708
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402708
Keywords
This article is cited by
-
Expression of immunoproteasome genes is regulated by cell-intrinsic and –extrinsic factors in human cancers
Scientific Reports (2016)
-
Chemical genomic screening identifies LY294002 as a modulator of glucocorticoid resistance in MLL-rearranged infant ALL
Leukemia (2014)
-
Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia
Leukemia (2012)
-
Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP–EBMT analysis
Leukemia (2012)
-
Current findings for recurring mutations in acute myeloid leukemia
Journal of Hematology & Oncology (2011)